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Abstract
Purpose of review—To highlight the important issues to consider in deciding whether to 
pursue and how to conduct medical surveillance for the emerging occupational and environmental 
respiratory diseases. It provides several recent examples illustrating implementation and 
usefulness of medical surveillance and the lessons learned from these experiences.
Recent findings—Medical surveillance conducted after sentinel outbreaks of constrictive 
bronchiolitis in microwave popcorn and flavoring production plants have shown the usefulness of 
this approach in documenting the burden of disease, identifying particular problem areas as targets 
for preventive interventions, and in tracking the progress. They have also identified the usefulness 
of longitudinal spirometry, which allows comparison of the individuals’ results to their own 
previous tests. The importance of recognizing a sentinel outbreak needing greater investigation is 
demonstrated by the cluster of cases of constrictive bronchiolitis recognized in military veterans 
returning from Iraq and Afghanistan. The World Trade Center disaster has demonstrated the 
importance of having baseline lung function data for future comparison and the importance of 
rapidly identifying exposed populations at greatest risk for health effects, and thus potentially 
having the greatest benefit from medical surveillance.
Summary—When used appropriately, medical surveillance is a useful tool in addressing the 
emerging occupational and environmental respiratory diseases by facilitating improvements in 
primary prevention and enabling interventions to help individuals through secondary prevention.
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INTRODUCTION
The World Health Organization defines an emerging disease as ‘one that has appeared in a 
population for the first time, or that may have existed previously but is rapidly increasing in 
incidence or geographic range’ [1]. Emerging occupational and environmental respiratory 
diseases meeting this definition continue to occur. Sometimes they are unanticipated. 
Earliest recognition of unanticipated emerging diseases depends on identifying sentinel 
cases or outbreaks, often through reporting by clinicians to public health agencies. Examples 
include alveolar proteinosis associated with indium tin oxide exposure [2■■] and 
constrictive bronchiolitis caused by exposure to diacetyl [3■]. Sometimes, emerging 
respiratory diseases are anticipated after potentially hazardous emerging occupational and 
environmental exposure scenarios are recognized. Examples include workers exposed to 
new nanomaterials [4■■] and exposures of residents and response workers in the wake of 
the World Trade Center (WTC) disaster [5]. After a sentinel event is recognized or it is 
recognized that an emerging exposure may lead to an emerging disease, there is often a 
desire to implement medical surveillance to assess disease burden, identify problem areas, 
target interventions, and track progress in disease prevention. However, in the setting of an 
emerging disease, there is often much uncertainty about whether medical surveillance would 
be sufficiently beneficial to merit its recommendation and, if so, how to implement it. This 
review will highlight the important issues to consider in making these decisions and provide 
several recent examples of medical surveillance for the emerging occupational and 
environmental respiratory diseases.
OVERVIEW OF MEDICAL SURVEILLANCE FOR THE EMERGING 
OCCUPATIONAL AND ENVIRONMENTAL RESPIRATORY DISEASES
Occupational health surveillance has been defined as ‘the ongoing systematic collection, 
analysis, and dissemination of exposure and health data on groups of workers for the 
purpose of preventing illness and injury’ [6]. Medical and hazard surveillance data are 
gathered for the practical purpose of assessing whether the preventive measures in place to 
protect workers are functioning effectively or whether gaps in these measures are allowing 
hazardous exposures and adverse health outcomes to occur. Occupational health surveillance 
is an essential part of a comprehensive occupational safety and health program.
Medical surveillance is the part of occupational health surveillance involving initial and 
periodic health evaluation of people who have had potentially hazardous work-related 
exposures. This ongoing effort can document individual sentinel cases of illness or, through 
evaluation of aggregated data, changes in population health. Findings can identify the 
problem areas that are opportunities for improvements in primary prevention. For example, 
if excess disease is associated with performing certain tasks or working in particular areas, 
this information can help in targeting the efforts to correct the situation. Another benefit of 
medical surveillance can be at the individual level. If surveillance identifies individuals at 
early stages of disease, it can trigger individual clinical interventions to prevent progression 
or even to reverse the disease process before it advances to greater severity. This is termed 
secondary prevention. If a major reason for conducting medical surveillance is to identify 
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the individuals who might benefit from secondary prevention, the surveillance is often 
referred to as ‘medical screening’ or ‘medical monitoring’.
It is challenging to design and implement a program of medical surveillance for an emerging 
occupational or environmental respiratory disease or in the face of an emerging potentially 
hazardous exposure. Uncertainty is a major challenge. Specific organ toxicities associated 
with emerging exposures may be poorly documented or unknown; this knowledge is needed 
to choose appropriate medical tests for use in surveillance. Exposure–response relationships 
may be unknown, making it difficult to target appropriate populations for surveillance. 
Favorable cost–benefit ratio is an important motivator of investment in medical surveillance. 
But cost–benefit of medical surveillance can often only be guessed at in emerging situations 
in which the population burden of emerging disease and the diagnostic performance of the 
medical tests chosen to screen a population for it are unknown.
Figure 1 shows a general approach that can be applied to medical surveillance in the setting 
of an emerging occupational and environmental respiratory disease. In making the decision 
whether to pursue medical surveillance, anticipation of potential disease emergence is very 
important. Once disease is anticipated and the decision is made to conduct medical 
surveillance, the next task is to design the specific surveillance program. A number of 
factors are important to consider (see list below). What is the target population for 
surveillance? Are there exposure groups anticipated to be at highest risk and thus the highest 
priority for surveillance? What medical tests should be performed? Respiratory symptom 
questionnaires can be quite useful in many settings. Objective medical testing will be guided 
by the type of disease that is anticipated. For example, spirometry may be chosen to monitor 
a population at risk for airways disease, and chest radiography to monitor a population at 
risk for pneumoconiosis. It is important to consider how often testing should be performed 
and over what period of time a population should be monitored. Surveillance must be 
conducted in a way that protects the individual confidentiality of results and is consistent 
with the ethical and legal requirements for confidentiality. Controls must be in place to 
allow the medical surveillance to be conducted and the data analyzed and used, but 
appropriately limit who has access to the data. A particular concern in occupational settings 
is protecting the confidentiality of workers’ sensitive medical information from their 
employers.
Individual medical surveillance results should be used to identify the candidates for 
secondary prevention and also to identify the sentinel cases that provide clues for 
improvements in primary prevention. It is important that workers be notified of their results 
and be provided access to guidance. Surveillance results should also be evaluated at the 
population level to assess whether there are associations of disease with certain work or 
exposure scenarios, which can guide efforts to improve primary prevention. It is important 
to act on these results as appropriate, as the desired outcomes of medical surveillance are 
improvements in primary prevention and secondary prevention. Lessons from the ongoing 
surveillance can be used to modify the surveillance program and improve it over time. Issues 
to consider in planning medical surveillance for the emerging occupational and 
environmental respiratory diseases are as follows:
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1. Does the balance of potential benefit vs. cost justify medical surveillance?
a. Challenge: there are many uncertainties in the setting of an emerging disease 
that make assessment of cost and benefit difficult.
2. What population should undergo surveillance?
a. Challenge: If the causative exposure is unclear and has not been adequately 
measured, it may be unclear which population is at greatest risk.
3. What medical tests should be used in the surveillance program?
a. Challenge: Performance of medical tests in surveillance for an emerging 
disease is often unclear.
4. How frequently should medical surveillance be conducted?
a. Challenge: Rapidity of emerging disease development may be unclear.
5. How long should medical surveillance continue?
a. Challenge: Latency of emerging disease development may be unclear.
6. How should individual data be used for secondary prevention?
a. Challenge: Clinicians may be unsure how to respond to some surveillance 
data (such as a significant decline in lung function from baseline that is still 
in the cross-sectional ‘normal range’).
7. How should aggregated population data be used to identify problem areas and 
improve primary prevention?
a. Challenge: Aggregated data should be managed in a way to protect 
individual confidentiality.
EXAMPLES OF MEDICAL SURVEILLANCE FOR UNANTICIPATED 
EMERGING OCCUPATIONAL AND ENVIRONMENTAL RESPIRATORY 
DISEASES
Flavoring-related lung disease provides an excellent example of the usefulness of medical 
surveillance in follow-up to a sentinel event [3■]. The first sentinel event related to 
respiratory disease caused by butter flavorings occurred in 2000, when an eight-person 
cluster of severe lung disease in a single microwave popcorn production plant was 
recognized and reported to the public health authorities. A detailed investigation of the plant 
followed. Medical surveillance of workers was conducted using respiratory questionnaires 
and spirometry. Exposure assessment studies were also performed. These studies eventually 
led to the realization that inhaling of vapors of a chemical used in butter flavorings, diacetyl, 
caused constrictive bronchiolitis. In addition, greater levels of exposure were related to 
greater loss of forced expiratory volume in 1 s (FEV1), and certain jobs and tasks, such as 
mixing flavors, were found to be associated with greatest risk. Similar medical surveillance 
in five additional microwave popcorn plants over the next several years identified additional 
previously unrecognized cases and demonstrated that this was an industry-wide issue. 
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Analysis of the aggregated data documented certain risk factors (e.g. mixing, working near 
nonisolated tanks of oil, and flavorings) and suggested strategies for primary prevention. 
Follow-up medical screening in the index plant after exposure controls were put into place 
documented reduced rate of FEV1 decline in workers as a measure of effectiveness [3■,7].
Two more sentinel events related to flavorings occurred in 2004 and 2006, when constrictive 
bronchiolitis occurred in two workers in flavoring-manufacturing plants in California [8]. 
These workers were exposed to diacetyl and other flavoring chemicals when they prepared 
batches of flavoring mixtures. In response, from 2006 to 2009, the California Division of 
Occupational Safety and Health (Cal/OSHA) and the California Department of Public 
Health implemented a state-wide program of occupational health surveillance in the flavor 
manufacturing industry that included medical surveillance and exposure assessment and 
control. The medical surveillance component included a respiratory health questionnaire and 
spirometry that was carried out at 3–6-month intervals. Initial cross-sectional medical 
surveillance identified 18 workers with spirometric obstruction (5 with an FEV1 that was 
severely reduced at <50% predicted) [9]. Follow-up rounds of medical surveillance 
demonstrated the utility of longitudinal spirometry in medical surveillance for this disease. It 
identified clusters of workers with abnormally rapid FEV1 decline in some flavor 
manufacturing companies. FEV1 decline was greater at companies using at least 800 pounds 
per year of diacetyl than at those using lesser amounts. One worker was reported with an 
FEV1 decline of 1.7l over only 8 months [10■].
As experience has accumulated about flavoring-related constrictive bronchiolitis, it has 
become clear that medical surveillance has an important role to play in primary and 
secondary prevention, that spirometry is a useful medical test for this surveillance, and that 
surveillance must be conducted relatively frequently because the disease can develop and 
progress quickly. In 2011, the National Institute for Occupational Safety and Health 
(NIOSH) issued draft guidelines for medical surveillance of workers exposed to diacetyl and 
a related alpha-diketone that is also used in butter flavorings, 2,3-pentanedione [11]. 
Medical surveillance is recommended for all workers who regularly work in or enter areas 
where diacetyl or 2,3-pentanedione are used or who have had these types of duties in the last 
year (follow-up should be longer if abnormalities are present). Medical surveillance should 
include a questionnaire that collects information about demographics, work history, 
exposures, personal risk factors, health history, and symptoms and spirometry. The 
recommended frequency of evaluation is every 6 months. However, if a likely case of work-
related lung disease is identified in the workplace, the frequency of evaluation for all similar 
workers should be increased to every 3 months and the workers instructed to report any new 
or worsening symptoms. This higher frequency is recommended to be maintained until 
excessive exposures have been corrected and no new cases have occurred for 12 months. 
Individuals identified as possibly having flavoring-related lung disease should undergo 
medical evaluation and be removed from exposure pending completion of the medical 
evaluation. Population data should be evaluated to assess for work-related risk factors based 
on job, task, area, and other exposure-related indices to guide interventions as needed.
Sentinel cases of ‘indolent constrictive bronchiolitis’ continue to be recognized in new 
occupational settings [12■]. Examples include among flavored coffee manufacturing 
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workers [13], fiberglass workers [14], and U.S. soldiers returning from Iraq and Afghanistan 
[15]. The latter exemplifies the challenges in determining appropriate recommendations for 
medical surveillance in the setting of a poorly understood emerging occupational and 
environmental respiratory disease. The sentinel event was recognition of a cluster of lung 
disease in soldiers returning from Iraq and Afghanistan. A total of 80 soldiers were 
evaluated because of dyspnea on exertion with inability to meet the military fitness standard 
for a 2-mile run. After evaluation, 49 were referred for lung biopsy. Thirty-eight soldiers had 
biopsy-confirmed constrictive bronchiolitis. A clear causative exposure was not identified. 
Medical tests were insensitive, with normal chest radiograph in 97%, normal chest 
computed tomography scan in 68%, and normal pulmonary function testing in 34% (13 of 
38). The only abnormal pulmonary function test abnormality in 19 of 38 was an isolated low 
carbon monoxide diffusing capacity. Had these soldiers not been recognized to be part of a 
concerning sentinel disease cluster, it is likely that many would not have undergone biopsy 
because screening tests would not have suggested the necessity.
Constrictive bronchiolitis in this population highlights the challenges in developing 
recommendations for medical surveillance for an emerging occupational and environmental 
respiratory disease, as was recently done by a working group assembled by the U.S. 
Department of Defense and the U.S. Department of Veterans Affairs [16■■]. Because the 
causative exposure is unclear, it is not possible to tightly target medical screening. 
Therefore, it is recommended that all U.S. troops deployed to Iraq and Afghanistan for at 
least 30 days should be in a medical surveillance program, and all deployed personnel 
should undergo predeployment and post-deployment respiratory disease surveillance. The 
recommended components of surveillance include administration of a questionnaire asking 
about smoking history, pertinent medical history, and respiratory symptoms; spirometry 
before and after bronchodilator; and exercise capacity evaluation, including 1 or 2 mile run 
times. Predeployment evaluation provides an important baseline, as many soldiers have 
‘super-normal’ test results at baseline and would have to lose much pulmonary function 
before dropping to conventional cross-sectional thresholds of abnormality. Criteria have 
been developed for recommending diagnostic referral based on the medical surveillance 
results, including changes exceeding certain percentages of baseline values [16■■].
EXAMPLES OF MEDICAL SURVEILLANCE FOR ANTICIPATED EMERGING 
OCCUPATIONAL AND ENVIRONMENTAL RESPIRATORY DISEASES
Identifying the best approach to medical surveillance for anticipated emerging diseases is 
extremely challenging. An excellent example of an emerging exposure is engineered 
nanoparticles. A recent report cautioned against rigid definitions, but noted that 
nanoparticles are often thought of as particles measuring 1–100 nm and exhibiting novel 
properties related to size [4■■]. There are many types of engineered nanoparticles, and new 
generations continue to emerge that are used in a wide range of products and industries. 
Examples of established products include ceramic nanoparticles, carbon nanotubes, and 
nanoporous materials. The economic impact of nano-enabled products in 2015 is estimated 
to be $2 trillion [4■■].
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Perhaps, because relatively little time has passed since the widespread introduction of 
nanomaterials, it is still unclear how exposure to them will affect the burden of respiratory 
disease in exposed people. Thus, recent NIOSH recommendations for medical surveillance 
of workers exposed to carbon nano-tubes and nanofibers were largely based on the animal 
toxicology studies showing that some of the tested materials had the ability to penetrate 
epithelial barriers and from lung into the pleura and circulation, to cause pulmonary 
inflammation and fibrosis, to interact with mitotic spindles and cause aneuploidy in daughter 
cells, and to increase the risk of lung cancer in mice co-exposed to a known carcinogen 
[17■■]. The evaluation of need for medical surveillance and how to perform it use this 
animal health data to anticipate potential human health problems. The recommended 
elements of surveillance include a baseline evaluation including a questionnaire, physical 
examination, spirometry, and a chest radiograph. Follow-up includes questionnaire and 
focused physical examination annually, spirometry every 3 years, and other evaluation as 
indicated.
Another type of setting in which emerging exposures occur and emerging diseases can be 
anticipated is after a large-scale disaster such as the WTC disaster. An important lesson in 
medical surveillance from that disaster was the importance that baseline medical information 
such as spirometry played in the follow-up of Fire Department of New York (FDNY) 
personnel after the disaster. The availability of baseline spirometry and other data (such as 
smoking history) allowed documentation of the pronounced declines in pulmonary function 
occurring soon after the disaster that would not otherwise have been possible [18]. Another 
effort involving medical monitoring, the WTC Health Registry, has enrolled 71 thousand 
participants, including workers, residents, and others with a high probability of exposure to 
WTC-related airborne contaminants. It is planned to evaluate them every 3–4 years over 20 
or more years. A recent article from the registry described the lessons learned, among them 
the importance of thoroughly documenting the exposures of the target population as quickly 
as possible during the disaster [5]. In a recent publication documenting the lessons learned 
from the Deepwater Horizon response, NIOSH investigators noted the importance of 
addressing the need for long-term follow-up studies early in a disaster, noting that such 
studies can be costly and difficult to design. They suggested that general areas of 
investigation might include etiologic investigations to evaluate the health impact of 
exposures to novel, under-studied agents; follow-up after exposure to agents with known 
adverse health effects and for which secondary prevention might be effective; or a 
combination of the two [19].
CONCLUSION
Medical surveillance is a useful tool in addressing the emerging occupational and 
environmental respiratory diseases. It can be applied after they are recognized in sentinel 
events or if they are anticipated as potential problems in people who have had hazardous 
exposures (Fig. 1). Before implementing medical surveillance, cost vs. benefit should be 
considered and if medical surveillance is felt to be appropriate, careful planning should 
determine who should undergo surveillance and how it should be carried out (see list above). 
Medical surveillance only achieves its full potential for benefit when surveillance 
information is analyzed and appropriately acted on at the individual level for secondary 
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prevention and population level to improve primary prevention. Lessons from the recent 
emerging occupational and environmental respiratory diseases such as constrictive 
bronchiolitis and WTC-associated respiratory disease include the importance of recognizing 
and acting on sentinel events; the importance of longitudinal follow-up of lung function and 
having access to baseline lung function measurements; and the importance of quickly 
identifying subpopulations with exposures, putting them at greatest risk for respiratory 
disease and thus at greatest potential benefit from medical surveillance.
REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been 
highlighted as:
■ of special interest
■■ of outstanding interest
1. World Health Organization. [Accessed 20 November 2013] Health topics. Emerging diseases. 
Available at http://www.who.int/topics/emerging_diseases/en/
2■■. Cummings KJ, Nakano M, Omae K, et al. Indium lung disease. Chest. 2012; 141:1512–1521. 
This international case series shows the spectrum of lung disease that has been associated with 
inhalation exposure to indium tin oxide. [PubMed: 22207675] 
3■. Kreiss K. Respiratory disease among flavoring-exposed workers in food and flavoring 
manufacture. Clin Pulm Med. 2012; 19:165–173. This review covers the evolving understanding 
of the agents that can cause flavoring-induced lung disease and the associated spectrum of 
clinical disease. 
4■■. National Academy of Sciences. A research strategy for environmental, health, and safety aspects 
of engineered nanomaterials. Washington, DC: The National Academies Press; 2012. This 
document provides an excellent introduction to the topic
5. Cone JE, Farfel M. World Trade Center Health Registry: a model for a nanomaterials exposure 
registry. Occup Environ Med. 2011; 53(Suppl 6):S48–S51.
6. National Institute for Occupational Safety and Health. Current intelligence bulletin 60. Interim 
guidance for medical screening and hazard surveillance for workers potentially exposed to 
engineered nanoparticles. Feb. 2009 DHHS (NIOSH) Publication no. 2009-116
7. Kanwal R, Kullman G, Fedan KB, et al. Occupational lung disease risk and exposure to butter-
flavoring chemicals after implementation of controls at a microwave popcorn plant. Pub Health 
Rep. 2011; 126:480–494. [PubMed: 21800743] 
8. Materna B, Quint J, Prudhomme J, et al. Fixed obstructive lung disease among workers in the 
flavor-manufacturing industry – California, 2004–2007. MMWR Morb Mortal Wkly Rep. 2007; 
56:389–393. [PubMed: 17464280] 
9. Kim TJ, Materna BL, Prudhomme JC, et al. Industry-wide medical surveillance of California flavor 
manufacturing workers: cross-sectional results. Am J Ind Med. 2010; 53:857–865. [PubMed: 
20564514] 
10■. Kreiss K, Fedan KB, Nasrullah M, et al. Longitudinal lung function declines among California 
flavoring manufacturing workers. Am J Ind Med. 2012; 55:657–668. An excellent example of the 
practical usefulness of using longitudinal spirometry for medical surveillance of flavoring-
exposed workers. [PubMed: 21932425] 
11. National Institute for Occupational Safety and Health. [Accessed 21 November 2013] Criteria for a 
recommended standard. Occupational exposure to diacetyl and 2,3-pentanedione (draft). Aug 12. 
2011 Available at http://www.cdc.gov/niosh/docket/archive/docket245.html
12■. Kreiss K. Occupational causes of constrictive bronchiolitis. Curr Opin Allergy Clin Immunol. 
2013; 13:167–172. A useful current review of the range of potential causes of constrictive 
bronchiolitis and the challenges posed by this condition. [PubMed: 23407121] 
Weissman Page 8
Curr Opin Allergy Clin Immunol. Author manuscript; available in PMC 2016 January 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
13. Huff S, Stocks JM, Saito R, et al. Obliterative bronchiolitis in workers in a coffee-processing 
facility – Texas, 2008–2012. MMWR Morb Mortal Wkly Rep. 2013; 62:305–307. [PubMed: 
23615673] 
14. Cullinan P, McGavin CR, Kreiss K, et al. Obliterative bronchiolitis in fibreglass workers: a new 
occupational disease? Occup Environ Med. 2013; 70:357–359. [PubMed: 23322914] 
15. King MS, Eisenberg R, Newman JH, et al. Constrictive bronchiolitis in soldiers returning from Iraq 
and Afghanistan. N Engl J Med. 2011; 365:222–230. [PubMed: 21774710] 
16■■. Rose C, Abraham J, Harkins D, et al. Overview and recommendations for medical screening 
and diagnostic evaluation for postdeployment lung disease in returning US warfighters. J Occup 
Environ Med. 2012; 54:746–751. An excellent overview of the respiratory health problems of 
this population and recommendations for medical screening and care. [PubMed: 22588477] 
17■■. National Institute for Occupational Safety and Health. Current intelligence bulletin 65. 
Occupational exposure to carbon nanotubes and nanofibers. Apr.2013 DHHS (NIOSH) 
Publication No. 2013-145. An excellent review of the topic and recommendations for prevention 
of adverse health effects in exposed workers. 
18. Aldrich TK, Gustave J, Hall CB, et al. Lung function in rescue workers at the World Trade Center 
after 7 years. N Engl J Med. 2010; 362:1263–1272. [PubMed: 20375403] 
19. Kitt MM, Decker JA, Delaney L, et al. Protecting workers in large-scale emergency responses. 
NIOSH experience in the Deepwater Horizon response. J Occup Environ Med. 2011; 53:711–715. 
[PubMed: 21697736] 
Weissman Page 9
Curr Opin Allergy Clin Immunol. Author manuscript; available in PMC 2016 January 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
KEY POINTS
• Medical surveillance can help to guide primary and secondary prevention 
efforts, and thus be a useful tool in addressing the emerging occupational and 
environmental respiratory diseases.
• Uncertainties can be a challenge, but before embarking on a program of medical 
surveillance for an emerging occupational and environmental respiratory 
disease, carefully consider whether the cost is balanced by potential for benefit 
and determine program specifics such as target population, tests to be 
performed, frequency of surveillance, duration of surveillance, and how data 
will be acted on at the individual and population level.
• Longitudinal spirometry with the comparison of individuals’ results to their own 
previous tests has emerged as a useful tool in respiratory medical surveillance 
and has been useful in the early detection of declines of pulmonary function in 
flavoring-induced lung disease, which can progress rapidly.
• Medical surveillance for emerging occupational and environmental respiratory 
disease after large-scale disasters is facilitated if baseline surveillance data 
already exist for the monitored population, and if the need for medical 
surveillance is determined relatively early on so that steps can be taken to assure 
collection of appropriate exposure information and to identify the exposed 
population that might benefit most from medical surveillance.
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FIGURE 1. 
General approach to medical surveillance for the emerging occupational and environmental 
respiratory diseases.
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